Amazing how Emma has managed to cling on through this shambles |
Yes, $1.33 is taking its toll. |
Strong £ doing the damage here and elsewhere creating a top up opportunity |
Should think that most of potential 'bad news' is priced in by now. A successful Delaware defence should see the price approach 2200p |
Unless the appeal in Delaware is unsuccessful, there's no other reason for that scenario to pass. |
Not so long ago GSK was down to 12 pounds, I wonder if we shall see that scenario again let us wait and see . |
Disastrous ! |
Quite a big markdown today which is not macro or sectoral. Hopefully not the beginning of a downtrend. Have to say that news of settling 2 cases vs 80000+ left can be taken as a negative. |
No, I think its less:
Former Zantac makers GSK, Pfizer, Sanofi and Boehringer Ingelheim are facing about 4,000 claims in California state court and about 2,000 in various other state courts around the country.
The bulk of the cases against GSK are in Delaware, where the British drugmaker faces more than 70,000 lawsuits. |
Only another 153000 to go-that's the problem. |
2 more Zantac settlements. |
 GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIXSource: Business WireTrial met primary endpoint, non-inferior immune response for both vaccines when co-administered compared with separate administrationCo-administration of the RSV and shingles adjuvanted vaccines was well tolerated, with acceptable reactogenicity and safety profilesThese data advance the science of co-administration of recommended adult vaccinesGSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) when co-administered with SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted), both AS01-adjuvanted vaccines (NCT05966090).1,2 The data were presented as a late-breaking abstract at the European Geriatric Medicine Society (EuGMS) Congress in Valencia, Spain (September 18-20th, 2024).2 SHINGRIX is approved for the prevention of shingles (herpes zoster) in adults aged 50 years and older. AREXVY is approved for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older, as well as individuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV. |
Short term it will head up and down with the market. Longer term I expect them to significantly outperform the market |
Same old GSK! |
Filtered for telling the truth! |
Spoole filtered for deramping... |
Heading back to the 1500s |
Blenrep (belantamab mafodotin) combinations in relapsed/refractory multiple myeloma accepted for regulatory review in Japan
· Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials
· If approved, Blenrep plus BorDex or PomDex could redefine relapsed/refractory multiple myeloma treatment landscape
· More than 7,200 new cases of multiple myeloma are diagnosed in Japan each year |
You must be confident of a few more quid on this if you're in at this price. I am too.. eventually! |
IN @ 1631.39 ..... ;o) |
Blenrep (belantamab mafodotin) in combination receives Breakthrough Therapy Designation in China for treatment of relapsed/refractory multiple myeloma.
Granted based on results from phase III head-to-head DREAMM-7 trial
Designation expedites development of investigational drugs with potential for substantial improvement over available therapies
Novel therapies needed in multiple myeloma as patients typically relapse or stop responding to initial treatments |
GSK announced positive results from a phase two trial of its mRNA-based seasonal flu vaccine on Thursday, showing improved immune responses against A and B strains in both younger and older adults compared to the standard of care. The FTSE 100 pharmaceuticals giant said the vaccine demonstrated strong antibody levels and an acceptable safety profile across all tested formulations. Based on the findings, GSK said it now planned to advance the vaccine program to phase three clinical trials. |
Issued: 12 September 2024, London UK
GSK announces positive headline data from phase II seasonal influenza mRNA vaccine programme
· A vaccine candidate formulation demonstrated positive A and B strain immune responses relative to standard of care in both younger and older adults
· mRNA platform elicits strong overall antibody titres with an acceptable safety profile
· Data support progression to phase III clinical trials
GSK plc (LSE/NYSE: GSK) today announced positive headline results of a phase II trial (NCT06431607) for its mRNA seasonal influenza vaccine programme. The trial studied a range of mRNA formulations in older and younger adults to evaluate vaccine candidates that could improve immune responses against influenza A and B strains, compared to the current standard of care.
In both younger and older adults, pre-defined success criteria were met. Interim data suggest the vaccine candidates have an acceptable safety and reactogenicity profile for all mRNA formulations tested.
These results build on the previous phase II trial and confirm the mRNA platform elicits strong overall antibody titres with an acceptable safety profile. With these results, the GSK mRNA seasonal influenza vaccine programme will progress into late-stage clinical development.
GSK's Chief Scientific Officer, Tony Wood said: "This marks a significant advancement in our mRNA programme and these data support moving into late-stage development. Ultimately, our goal is to develop a new best-in-class vaccine to bring greater protection to people through the influenza season."
GSK recently signed a new licensing agreement with CureVac to assume full control of developing and manufacturing influenza and COVID-19 candidate vaccines. GSK continues to develop and optimise its mRNA capabilities through investments and partnerships, including in AI/ML-based sequence optimisation, nanoparticle design and manufacturing.
About study NCT06431607
The phase II study assesses the reactogenicity, safety, and immunogenicity of different dose levels of a modified, multivalent vaccine candidate, encoding antigens matched to all three WHO-recommended influenza strains. The study includes 250 healthy younger adults aged 18 to 64 and 250 healthy older adults aged 65 to 85. In each age group, different dose levels were tested in comparison to an age-appropriate, licensed comparator vaccine.
|
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
